Citations

Clear

6273 citation(s) found for "To, Andrew".

Experimental Sleep Restriction Causes Endothelial Dysfunction in Healthy Humans
Calvin, Andrew D. , Covassin, Naima , Kremers, Walter K. , Adachi, Taro, Macedo, Paula , Bukartyk, Jan , Davison, Diane E., Levine, James A. , Singh, Prachi , Wang, Shihan , Albuquerque, Felipe N. , Somers, Virend K. , Singh, Prachi , Calvin, Andrew D , Kremers, Walter K

Mayo Clinic

Journal of the American Heart Association | November 25, 2014 | Volume: 3 | Issue: 6 | Pages: No page available

10.1161/jaha.114.001143 | PMID 25424573 Get It

Background Epidemiologic evidence suggests a link between short sleep duration and cardiovascular risk, although the nature of any relationship and mechanisms remain unclear. Short sleep duration has also been linked to an increase in cardiovascular events. Endothelial dysfunction has itself been implicated as a mediator of heightened cardiovascular risk. We sought to determine the effect of 8 days/8 nights of partial sleep restriction on endothelial function in healthy humans. Methods and Results Sixteen healthy volunteers underwent a randomized study of usual sleep versus sleep restriction of two‐thirds normal sleep time for 8 days/8 nights in a hospital‐based clinical research unit. The main outcome was endothelial function measured by flow‐mediated brachial artery vasodilatation ( FMD ). Those randomized to sleep restriction slept 5.1 hours/night during the experimental period compared with 6.9 hours/night in the control group. Sleep restriction was associated with significant impairment in FMD (8.6±4.6% during the initial pre‐randomization acclimation phase versus 5.2±3.4% during the randomized experimental phase, P =0.01) whereas no change was seen in the control group (5.0±3.0 during the acclimation phase versus 6.73±2.9% during the experimental phase, P =0.10) for a between‐groups difference of −4.40% (95% CI −7.00 to −1.81%, P =0.003). No change was seen in non‐flow mediated vasodilatation ( NFMD ) in either group. Conclusion In healthy individuals, moderate sleep restriction causes endothelial dysfunction. Clinical Trial Registration URL : ClinicalTrials.gov. Unique identifier: NCT 01334788.
Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis
Foureau, David , Walling, Tracy L., Maddukuri, Vinaya C. , Anderson, William E. , Culbreath, Katherine , Ahrens, Will, Jacobs, C., Watkins, Paul B. , Chalasani, Naga , Talwalkar, Jayant A., Lee, W.M., Stolz, Andrew , Bonkovsky, Herbert L. , Kleiner, David Erwin , Fontana, Robert J. , Serrano, José , Foureau, David

Mayo Clinic

Clinical and Experimental Immunology | November 23, 2014 | Volume: 180 | Issue: 1 | Pages: 40-51

10.1111/cei.12558 | PMID 25418487 Get It

Summary Drug-induced liver injury (DILI) is often caused by innate and adaptive host immune responses. Characterization of inflammatory infiltrates in the liver may improve understanding of the underlying pathogenesis of DILI. This study aimed to enumerate and characterize leucocytes infiltrating liver tissue from subjects with acute DILI (n = 32) versus non-DILI causes of acute liver injury (n = 25). Immunostains for CD11b/CD4 (Kupffer and T helper cells), CD3/CD20 (T and B cells) and CD8/CD56 [T cytotoxic and natural killer (NK) cells] were evaluated in biopsies from subjects with acute DILI, either immunoallergic (IAD) or autoimmune (AID) and idiopathic autoimmune (AIH) and viral hepatitis (VH) and correlated with clinical and pathological features. All biopsies showed numerous CD8+ T cells and macrophages. DILI cases had significantly fewer B lymphocytes than AIH and VH and significantly fewer NK cells than VH. Prominent plasma cells were unusual in IAD (three of 10 cases), but were associated strongly with AIH (eight of nine) and also observed in most with AID (six of nine). They were also found in five of 10 cases with VH. Liver biopsies from subjects with DILI were characterized by low counts of mature B cells and NK cells in portal triads in contrast to VH. NK cells were found only in cases of VH, whereas AIH and VH both showed higher counts of B cells than DILI. Plasma cells were associated most strongly with AIH and less so with AID, but were uncommon in IAD.
A safety study on intrathecal delivery of autologous mesenchymal stromal cells in rabbits directly supporting Phase I human trials
Chen, Bingkun K. , Staff, Nathan P. , Nesbitt, Jarred J., Butler, Greg W., Padley, Douglas, Parisi, Joseph E. , Dietz, Allan B. , Windebank, Anthony J. , Knight, Andrew M, Padley, Douglas J, Knight, Andrew Michael , Staff, Nathan P , Dietz, Allan B

Mayo Clinic

Transfusion | November 21, 2014 | Volume: 55 | Issue: 5 | Pages: 1013-1020

10.1111/trf.12938 | PMID 25413276 Get It

BackgroundThere are no effective treatments that slow the progression of neurodegenerative diseases. A major challenge of treatment in neurodegenerative diseases is appropriate delivery of pharmaceuticals into the cerebrospinal fluid (CSF) of affected individuals. Mesenchymal stromal cells (MSCs—either naïve or modified) are a promising therapy in neurodegenerative diseases and may be delivered directly into the CSF where they can reside for months. In this preclinical study, we evaluated the safety of intrathecal autologous MSCs in a rabbit model.Study Design and MethodsAutologous adipose‐derived MSCs (or artificial CSF) were delivered intrathecally, either with single or with repeated injections into the foramen magnum of healthy rabbits and monitored for 4 and 12 weeks, respectively.ResultsRabbits tolerated injections well and no definitive MSC‐related side effects were observed apart from three rabbits that had delayed death secondary to traumatic foramen magnum puncture. Functional assessments and body weights were equivalent between groups. Gross pathology and histology did not reveal any abnormalities or tumor growth. Complete blood count data were normal and there were no differences in CSF interleukin‐6 levels in all groups tested.ConclusionOur data suggest that intrathecal delivery of autologous MSCs is safe in a rabbit model. Data from this study have supported two successful investigational new drug applications to the Food and Drug Administration, resulting in the initiation of two clinical trials using autologous MSCs in amyotrophic lateral sclerosis and multiple system atrophy.
Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation
Reece, Donna , Beksaç, Meral , Spencer, Andrew , Sonneveld, Pieter , Kalimi, Ghulam H., Shi, Michael, Scott, Jeffrey W., Stewart, A. Keith, Beksaç, Meral , Scheid, Christof , Callander, Natalie S. , Cai, Can , Beksac, Meral

Mayo Clinic

European Journal of Haematology | November 17, 2014 | Volume: 95 | Issue: 4 | Pages: 316-324

10.1111/ejh.12491 | PMID 25402977 Get It

AbstractObjectivesApproximately 15% of patients with multiple myeloma (MM) exhibit a t(4;14) translocation, which often results in constitutive activation of the receptor tyrosine kinase (RTK) fibroblast growth factor receptor 3 (FGFR3). This study evaluated the efficacy and safety of dovitinib, an RTK inhibitor with in vitro inhibitory activity against FGFR, in patients with relapsed or refractory MM with or without t(4;14) translocation.MethodsAdult patients with relapsed or refractory MM who had received ≥2 prior regimens were enrolled in this multicenter, 2‐stage, phase 2 trial. Patients were grouped based on their t(4;14) status. Dovitinib (500 mg/day orally) was administered on a 5‐days‐on/2‐days‐off schedule. The primary endpoint was overall response rate by local investigator review (per International Myeloma Working Group criteria). In non‐responding patients, treatment could continue with the addition of low‐dose dexamethasone.ResultsIn total, 43 patients (median age, 63 years) were enrolled (13 t(4;14) positive, 26 t(4;14) negative, and 4 t(4;14) status non‐interpretable). Patients had received a median of 5 prior regimens. Median duration of treatment was 8.7 weeks in the t(4;14)‐positive group and 3.7 weeks in the t(4;14)‐negative group. None of the patients on dovitinib had objective responses. The stable disease rate was 61.5% in the t(4;14)‐positive group and 34.6% in the t(4;14)‐negative group. Overall, 39 patients (90.7%) had adverse events suspected to be related to study drug, most commonly diarrhea (60.5%), nausea (58.1%), vomiting (46.5%), and fatigue (32.6%).ConclusionDovitinib showed no single‐agent activity in relapsed or refractory MM but may stabilize disease in some t(4;14)‐positive patients.
Self‐rated and informant‐rated everyday function in comparison to objective markers of Alzheimer's disease
Rueda, Alicia D., Saito, Naomi , Harvey, Danielle , Risacher, Shannon L. , Aisen, Paul , Petersen, Ronald C. , Saykin, Andrew J. , Farias, Sarah Tomaszewski , Initiative, Alzheimer's Disease Neuroimaging, Lau, Karen M. , Initiative, Alzheimer's Disease Neuroimaging, Saykin, Andrew J , Harvey, Danielle J

Mayo Clinic

Alzheimer's & Dementia | November 17, 2014 | Volume: 11 | Issue: 9 | Pages: 1080-1089

10.1016/j.jalz.2014.09.002 | PMID 25449531 Get It

It is recognized that individuals with mild cognitive impairment (MCI) already demonstrate difficulty in aspects of daily functioning, which predicts disease progression. This study examined the relationship between self‐ versus informant‐report of functional ability, and how those reports relate to objective disease measures across the disease spectrum (i.e. cognitively normal, MCI, Alzheimer's disease). A total of 1080 subjects with self‐ and/or informant‐rated Everyday Cognition questionnaires were included. Objective measures included cognitive functioning, structural brain atrophy, cerebrospinal fluid abnormalities, and a marker of amyloid deposition using positron emission tomography with [ 18 F]AV45 (florbetapir). Overall, informant‐report was consistently more associated with objective markers of disease than self‐report although self‐reported functional status may still have some utility in early disease.
The Effect of an Electronic Checklist on Critical Care Provider Workload, Errors, and Performance
Harrison, Andrew M. , O’Horo, John C. , Berrios, Ronaldo A. Sevilla, Pickering, Brian W. , Herasevich, Vitaly , O'Horo, John C, Thongprayoon, Charat , Berrios, Ronaldo Sevilla , Harrison, Andrew Marc , O'Horo, John C , Herasevich, Vitaly

Mayo Clinic

Journal of Intensive Care Medicine | November 12, 2014 | Volume: 31 | Issue: 3 | Pages: 205-212

10.1177/0885066614558015 | PMID 25392010 Get It

Purpose: The strategy used to improve effective checklist use in intensive care unit (ICU) setting is essential for checklist success. This study aimed to test the hypothesis that an electronic checklist could reduce ICU provider workload, errors, and time to checklist completion, as compared to a paper checklist. Methods: This was a simulation-based study conducted at an academic tertiary hospital. All participants completed checklists for 6 ICU patients: 3 using an electronic checklist and 3 using an identical paper checklist. In both scenarios, participants had full access to the existing electronic medical record system. The outcomes measured were workload (defined using the National Aeronautics and Space Association task load index [NASA-TLX]), the number of checklist errors, and time to checklist completion. Two independent clinician reviewers, blinded to participant results, served as the reference standard for checklist error calculation. Results: Twenty-one ICU providers participated in this study. This resulted in the generation of 63 simulated electronic checklists and 63 simulated paper checklists. The median NASA-TLX score was 39 for the electronic checklist and 50 for the paper checklist ( P = .005). The median number of checklist errors for the electronic checklist was 5, while the median number of checklist errors for the paper checklist was 8 ( P = .003). The time to checklist completion was not significantly different between the 2 checklist formats ( P = .76). Conclusion: The electronic checklist significantly reduced provider workload and errors without any measurable difference in the amount of time required for checklist completion. This demonstrates that electronic checklists are feasible and desirable in the ICU setting.
Characterization of myocardial iron overload by dual-energy computed tomography compared to T2* MRI. A phantom study
Ibrahim, El-Sayed H. , Bowman, Andrew W.

Mayo Clinic

2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society | November 12, 2014 | Volume: No volume available | Issue: No issue available | Pages: 5133-5136

10.1109/embc.2014.6944780 | PMID 25571148 Get It

Ureteral Cannulation as a Complication of Urethral Catheterization
Anderson, Bradley W., Greenlund, Andrew C.

Mayo Clinic

Korean Journal of Urology | November 12, 2014 | Volume: 55 | Issue: 11 | Pages: 768

10.4111/kju.2014.55.11.768 | PMID 25405021 Get It

Percutaneous Clinical T 1a Renal Mass Ablation in the Octogenarian and Nonagenarian: Oncologic Outcomes and Morbidity
Miller, Andrew , Schmit, Grant D. , Weisbrod, Adam J. , Boorjian, Stephen A. , Thompson, R. Houston, Lohse, Christine M. , Kor, Darryl J., Callstrom, Matthew R. , Atwell, Thomas D. , Miller, Andrew J. , Kurup, A. Nicholas

Mayo Clinic

Journal of Endourology | November 11, 2014 | Volume: 29 | Issue: 6 | Pages: 671-676

10.1089/end.2014.0733 | PMID 25386995 Get It

Short Myelitis Lesions in Aquaporin-4-IgG–Positive Neuromyelitis Optica Spectrum Disorders
Flanagan, Eoin P. , Weinshenker, Brian G. , Krecke, Karl N. , Lennon, Vanda A. , Lucchinetti, Claudia F. , McKeon, Andrew , Wingerchuk, Dean M. , Shuster, Elizabeth A., Jiao, Yujuan , Horta, Erika , Pittock, Sean J. , Horta, Erika S, Pittock, S J , Flanagan, E P , Weinshenker, Brian G , McKeon, Andrew

Mayo Clinic

JAMA Neurology | November 10, 2014 | Volume: 72 | Issue: 1 | Pages: 81

10.1001/jamaneurol.2014.2137 | PMID 25384099 Get It